Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Treatment with LB-102 resulted in a positive shift in disease severity as measured by mean change from baseline in Clinical Global Impression of Severity (CGI-S) scores Phase 3 clinical trial of...
-
NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases including...
-
Robust 359 patient trial met primary endpoint with statistically significant reduction in PANSS total score at all dose levels compared to placebo Clinically meaningful effect sizes were...
-
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...
-
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases, including...
-
Turner, a seasoned biotechnology executive, was formerly CEO of Carmot Therapeutics, which was acquired by Roche in 2024 for $2.7 billion LB Pharma’s lead asset, LB-102, is a patent protected...